Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Working Capital Changes (2022 - 2025)

Atara Biotherapeutics' Other Working Capital Changes history spans 4 years, with the latest figure at -$16000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 99.92% year-over-year to -$16000.0; the TTM value through Dec 2025 reached -$15000.0, up 99.93%, while the annual FY2025 figure was -$15000.0, 99.93% up from the prior year.
  • Other Working Capital Changes reached -$16000.0 in Q4 2025 per ATRA's latest filing, down from $4.2 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $74.9 million in Q2 2025 to a low of -$79.1 million in Q1 2025.
  • Average Other Working Capital Changes over 4 years is -$3.0 million, with a median of -$68000.0 recorded in 2024.
  • Peak YoY movement for Other Working Capital Changes: tumbled 99.26% in 2023, then soared 110275.0% in 2025.
  • A 4-year view of Other Working Capital Changes shows it stood at -$11.6 million in 2022, then dropped by 10.09% to -$12.8 million in 2023, then crashed by 60.88% to -$20.6 million in 2024, then soared by 99.92% to -$16000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Other Working Capital Changes are -$16000.0 (Q4 2025), $4.2 million (Q3 2025), and $74.9 million (Q2 2025).